
NYSEHealthcareDrug Manufacturers - Specialty & Generic
最新数据
US$75.65
+US$0.84 · +1.12%
Zoetis Inc. stands as a global leader in animal health, focusing on the research, development, manufacturing, and commercialization of veterinary pharmaceuticals, vaccines, and diagnostic tools. Its comprehensive portfolio serves a broad spectrum of species, encompassing both livestock, including cattle, swine, poultry, fish, and sheep, and beloved companion animals such as dogs, cats, and horses. Among its pharmaceutical offerings are various therapeutic agents. This includes vaccines, vital for preventing respiratory, gastrointestinal, and reproductive diseases by stimulating a targeted immune response; anti-infectives that combat or inhibit the proliferation of bacterial, fungal, or protozoal pathogens; and parasiticides aimed at eradicating both internal and external pests such as fleas, ticks, and various worms. Additional pharmaceuticals address areas such as pain management and sedation, anti-emesis, reproductive health, and oncology. The portfolio also features dermatological solutions for allergic skin conditions and atopic dermatitis, alongside medicated feed additives specifically designed for livestock. Beyond therapeutics, Zoetis offers an extensive array of diagnostic solutions. These include portable analysis systems for blood and urine, point-of-care testing devices, specialized instruments and reagents, rapid immunoassay kits, comprehensive reference laboratory services, and blood glucose monitoring equipment. Further extending its reach, the company provides supplementary offerings such as nutritional products, agribusiness support services, biodevices, genetic testing, and innovations in precision animal health. Zoetis distributes its diverse product portfolio to a broad customer base, including veterinary professionals, livestock producers, and retail channels. This distribution occurs directly via its sales representatives and technical specialists, as well as through partnerships with third-party veterinary distributors. Established in 1952, the company maintains its corporate headquarters in Parsippany, New Jersey.
前收盘价
US$75.65
+US$0.84 · +1.12%
盘后
US$75.50
−US$0.15 · -0.20%
10月12日 18:09 ET
盘中时间采用ET。市场数据可能有所延迟。
Zoetis Inc. stands as a global leader in animal health, focusing on the research, development, manufacturing, and commercialization of veterinary pharmaceuticals, vaccines, and diagnostic tools. Its comprehensive portfolio serves a broad spectrum of species, encompassing both livestock, including cattle, swine, poultry, fish, and sheep, and beloved companion animals such as dogs, cats, and horses. Among its pharmaceutical offerings are various therapeutic agents. This includes vaccines, vital for preventing respiratory, gastrointestinal, and reproductive diseases by stimulating a targeted immune response; anti-infectives that combat or inhibit the proliferation of bacterial, fungal, or protozoal pathogens; and parasiticides aimed at eradicating both internal and external pests such as fleas, ticks, and various worms. Additional pharmaceuticals address areas such as pain management and sedation, anti-emesis, reproductive health, and oncology. The portfolio also features dermatological solutions for allergic skin conditions and atopic dermatitis, alongside medicated feed additives specifically designed for livestock. Beyond therapeutics, Zoetis offers an extensive array of diagnostic solutions. These include portable analysis systems for blood and urine, point-of-care testing devices, specialized instruments and reagents, rapid immunoassay kits, comprehensive reference laboratory services, and blood glucose monitoring equipment. Further extending its reach, the company provides supplementary offerings such as nutritional products, agribusiness support services, biodevices, genetic testing, and innovations in precision animal health. Zoetis distributes its diverse product portfolio to a broad customer base, including veterinary professionals, livestock producers, and retail channels. This distribution occurs directly via its sales representatives and technical specialists, as well as through partnerships with third-party veterinary distributors. Established in 1952, the company maintains its corporate headquarters in Parsippany, New Jersey.
日内区间
当前US$75.65
52周区间
当前US$75.65
盘中时间采用ET。市场数据可能有所延迟。
GoAI 评分
买入
估值
96
深度低估
情绪
66
看涨
风险
43
风险偏高
动量
25
动能减弱
完整 GoAI 研究
继续查看更深入的依据、催化因素和风险。
Zoetis Inc. stands as a global leader in animal health, focusing on the research, development, manufacturing, and commercialization of veterinary pharmaceuticals, vaccines, and diagnostic tools. Its comprehensive portfolio serves a broad spectrum of species, encompassing both livestock, including cattle, swine, poultry, fish, and sheep, and beloved companion animals such as dogs, cats, and horses. Among its pharmaceutical offerings are various therapeutic agents. This includes vaccines, vital for preventing respiratory, gastrointestinal, and reproductive diseases by stimulating a targeted immune response; anti-infectives that combat or inhibit the proliferation of bacterial, fungal, or protozoal pathogens; and parasiticides aimed at eradicating both internal and external pests such as fleas, ticks, and various worms. Additional pharmaceuticals address areas such as pain management and sedation, anti-emesis, reproductive health, and oncology. The portfolio also features dermatological solutions for allergic skin conditions and atopic dermatitis, alongside medicated feed additives specifically designed for livestock. Beyond therapeutics, Zoetis offers an extensive array of diagnostic solutions. These include portable analysis systems for blood and urine, point-of-care testing devices, specialized instruments and reagents, rapid immunoassay kits, comprehensive reference laboratory services, and blood glucose monitoring equipment. Further extending its reach, the company provides supplementary offerings such as nutritional products, agribusiness support services, biodevices, genetic testing, and innovations in precision animal health. Zoetis distributes its diverse product portfolio to a broad customer base, including veterinary professionals, livestock producers, and retail channels. This distribution occurs directly via its sales representatives and technical specialists, as well as through partnerships with third-party veterinary distributors. Established in 1952, the company maintains its corporate headquarters in Parsippany, New Jersey.
日内区间
当前US$75.65
52周区间
当前US$75.65
盈利能力占已公布营收的百分比。
营收
营业利润
净利润
| 项目(USD) | 2025财年 | 2024财年 | 2023财年 | 2022财年 | 2021财年 |
|---|---|---|---|---|---|
| 营收 | 94.67亿 USD | 92.56亿 USD | 85.44亿 USD | 80.8亿 USD | 77.76亿 USD |
| 销货成本 | 27.94亿 USD | 28.6亿 USD | 27.1亿 USD | 26.04亿 USD | 24.64亿 USD |
| 毛利 | 66.73亿 USD | 63.96亿 USD | 58.34亿 USD | 54.76亿 USD | 53.12亿 USD |
| 研究与开发 | 6.98亿 USD | 6.86亿 USD | 6.14亿 USD | 5.39亿 USD | 5.08亿 USD |
| 销售、一般及管理费用 | 23.78亿 USD | 23.18亿 USD | 21.51亿 USD | 20.09亿 USD | 20.01亿 USD |
| 营业费用 | 30.76亿 USD | 30.04亿 USD | 27.65亿 USD | 25.48亿 USD | 25.09亿 USD |
| 利息收入 | 9300万 USD | 1.06亿 USD | 1.05亿 USD | 5000万 USD | 600万 USD |
| 利息支出 | 2.43亿 USD | 2.42亿 USD | 2.58亿 USD | 2.37亿 USD | 2.36亿 USD |
| 折旧和摊销 | 4.87亿 USD | 4.97亿 USD | 4.91亿 USD | 4.65亿 USD | 4.48亿 USD |
| 营业利润 | 35.97亿 USD | 33.92亿 USD | 30.69亿 USD | 29.28亿 USD | 28.03亿 USD |
| 净利润 | 26.73亿 USD | 24.86亿 USD | 23.44亿 USD | 21.14亿 USD | 20.37亿 USD |
公司数据更新于 2026年10月13日。
近期已公布业绩
近期已公布业绩
第三方分析师预期可能变化,并非 GoAI 建议。
平均目标
US$87.33
上涨空间 15.44%年度分割调整后的每股现金分配。
US$2.00
2025年(完整年度)+100.0% 自从 2021
2026年(部分年度):US$1.59
US$1.00
2,021
US$1.30
2,022
US$1.50
2,023
US$1.728
2,024
US$2.00
2,025
US$1.59
2,026*
* 在现有股息历史记录中,该日历年仅包含部分期间。
| 行动 | 除息日 | 详情 | 记录日期 | 付款日期 |
|---|---|---|---|---|
股息即将实施 | 2026年10月30日 | US$0.53Quarterly | 2026年10月30日 | 2026年12月1日 |
股息 | 2026年7月20日 | US$0.53Quarterly | 2026年7月20日 | 2026年9月1日 |
股息 | 2026年4月20日 | US$0.53Quarterly | 2026年4月20日 | 2026年6月2日 |
股息 | 2026年1月20日 | US$0.53Quarterly | 2026年1月20日 | 2026年3月3日 |
股息 | 2025年10月31日 | US$0.50Quarterly | 2025年10月31日 | 2025年12月2日 |
股息 | 2025年7月18日 | US$0.50Quarterly | 2025年7月18日 | 2025年9月3日 |
除息 2026年10月30日
US$0.53
Quarterly
2026年10月30日登记 · 支付日 2026年12月1日
除息 2026年7月20日
US$0.53
Quarterly
2026年7月20日登记 · 支付日 2026年9月1日
除息 2026年4月20日
US$0.53
Quarterly
2026年4月20日登记 · 支付日 2026年6月2日
除息 2026年1月20日
US$0.53
Quarterly
2026年1月20日登记 · 支付日 2026年3月3日
除息 2025年10月31日
US$0.50
Quarterly
2025年10月31日登记 · 支付日 2025年12月2日
除息 2025年7月18日
US$0.50
Quarterly
2025年7月18日登记 · 支付日 2025年9月3日
报告持有此股票敞口的交易所交易基金。
State Street SPDR S&P 500 ETF1557.T595.42亿0.05%130.34万亿 JPY0.09%JP¥123,000+0.12%
Vanguard Morningstar Total Stock Market ETFVTI9.25亿0.04%2.3万亿 USD0.03%US$381.57-0.10%
Vanguard S&P 500 ETFVOO8.59亿0.05%1.8万亿 USD0.03%US$715.13-0.06%
Vanguard Morningstar Mid-Cap ETFVO6.29亿0.28%2264亿 USD0.03%US$80.92-0.27%
iShares Core S&P 500 ETFIVV4.11亿0.05%8964.4亿 USD0.03%US$781.44-0.07%
State Street SPDR S&P 500 ETFSPY3.75亿0.05%8216.79亿 USD0.09%US$778.1-0.06%
Vanguard Morningstar Value ETFVTV2.78亿0.11%2624亿 USD0.03%US$221.43+0.38%
VanEck Morningstar Wide Moat ETFMOAT2.75亿2.38%115.3亿 USD0.46%US$109.26+0.48%
State Street SPDR S&P 500 ETF1557.T
Vanguard Morningstar Total Stock Market ETFVTI
Vanguard S&P 500 ETFVOO
Vanguard Morningstar Mid-Cap ETFVO
iShares Core S&P 500 ETFIVV
State Street SPDR S&P 500 ETFSPY
Vanguard Morningstar Value ETFVTV
VanEck Morningstar Wide Moat ETFMOATAI 生成内容及延迟市场数据仅供信息与教育用途,不构成投资建议。